Latest newsletter
IPN Members Newsletter · October 2026
A very spooky October to everyone!
Read the newsletter →
From your inbox
Past issues
IPN Members Newsletter - August 2026
Read the newsletter → IPN Members Newsletter - August 2026
IPN Members Newsletter - July 2026
Read the newsletter → IPN Members Newsletter - July 2026
IPN Members Newsletter - June 2026
Read the newsletter → IPN Members Newsletter - June 2026
IPN Members Newsletter - May 2026
Read the newsletter → IPN Members Newsletter - May 2026IPN blog
Written by members
Research summaries and policy explainers from IPN members.
DEA Proposes Schedule I Classification for Five Research Tryptamines
The rule would place five lesser-known serotonergic compounds into the most restrictive category of the Controlled Substances Act, potentially creating new barriers to pharmacological research.
Read post → DEA Proposes Schedule I Classification for Five Research Tryptamines
The FDA’s Next Step on Psychedelic Medicine
A look at the FDA’s upcoming public discussion of psychedelic medicine and its implications for research.
Read post → The FDA’s Next Step on Psychedelic Medicine
What Remains After the Trip?
Two recent neuroimaging studies offer a more rigorous account of how psychedelics temporarily reorganize the brain and what may persist after the experience.
Read post → What Remains After the Trip?